CryoPort, Inc. · NASDAQ:CYRX
CryoPort — Q3 2026 Earnings Presentation
18 slides from CryoPort's earnings presentation, Nov 5, 2026
Slide 1: Q3 2026 Earnings Deck
Q3 2026 Earnings Deck November 5th, 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements Forward-Looking Statements Statements in this press release which are not purely historical, including statements regarding the Company's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking stateme
Slide 3: Cryoport – Trusted Partner to Life Sciences Companies
Cryoport – Trusted Partner to Life Sciences Companies Life sciences company focused on providing mission critical, proprietary temperature-controlled supply chain solutions Capabilities include core competencies to ship, store and deliver biologics in a cryogenic or temperature-controlled state such
Slide 4: The Cryoport Platform: Services & Products
The Cryoport Platform: Services & Products Core services and products supporting the management of critical biomaterials Life Sciences Services 57% Life Sciences Products 43% +18% YoY +8% YoY Q3 FY2026 Q3 FY2026 BioLogistics IntegriCell® BioServices BioStorage Cryogenic Systems (Launched in 2024) (L
Slide 5: Cryoport Snapshot – By the Numbers
Cryoport Snapshot – By the Numbers Leading integrated platform ensuring the integrity of critical biomaterials across the life sciences value chain $50.2M $197M-$199M 47.5% $1.1M +14% Organic Growth +12%* Organic Growth -75bps YoY +$1.8M FY2026E Q3 FY2026 Revenue Updated Revenue Guidance from Q3 FY2
Slide 6: Revenue from Supporting Commercial Cell and Gene Therapies
Revenue from Supporting Commercial Cell and Gene Therapies Q1 2025 through Q3 2026 © 2026 CRYOPORT, INC. 6
Slide 7: Q3 2026 Revenue Drivers
Q3 2026 Revenue Drivers Strong growth across the platform of products and services offerings +18% Cell & Gene Therapy Revenue Life Sciences Services Revenue +20% +15% Commercial +8% Clinical Trial Cell & Gene Cell & Gene Therapy Therapy Life Sciences +25% Revenue Products BioServices & Revenue Reven
Slide 8: Patients First: Supporting the Therapies of Tomorrow
Patients First: Supporting the Therapies of Tomorrow Clinical Trials Supported, by Trial Phase Phase I Phase II Phase III Quarterly Trial count as of the end of the respective periods © 2026 CRYOPORT, INC. 8
Slide 9: Supporting Commercial Cell and Gene Therapies Globally
Supporting 23 Commercial Cell and Gene Therapies Globally アクーゴ AKUUGO® © 2026 CRYOPORT, INC. 9
Slide 10: Cryoport, Inc. Global Locations
Cryoport, Inc. Global Locations Amsterdam, NL Global Logistics Center Morris Plains, NJ Global Supply Chain Center Stevenage, UK Tokyo, Japan Supply Chain Hub Global Logistics Center New Prague, MN Darmstadt, DE Manufacturing Facility Tec4med Lifescience Chengdu, China Manufacturing Facility Nashvil
Slide 11: Driving Bottom-Line Improvement
Driving Bottom-Line Improvement 47.5% $1.1M $393.1M Gross Margin Adjusted EBITDA Cash and from Continuing from Continuing Short-Term Operations Operations Investment © 2026 CRYOPORT, INC. 11
Slide 12: Global Cell and Gene Therapy Market
Global Cell and Gene Therapy Market $143.6B 2034E $16.5B 2026 5.04 6.42 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2021–2034 ($ Billion) www.fortunebusinessinsights.com © 2026 CRYOPORT, INC. 12
Slide 13: 2026 CGT Investment Significantly Outpacing 2025
2026 CGT Investment Significantly Outpacing 2025 $20 $11.3B+ $15.2 Total sector financings $15 through Q3 2026* $11.7 $11.3 $11.2 $10 +43% $5 $7.9B Q1–Q3 2025 YoY increase from Q1 – Q3 2025 $- FY2023 FY2024 FY2025 Q1 - Q3 2026 Reporting Period $ Billion *Q3 2026 Data is Preliminary Source: Alliance
Slide 14: Q3-2026 Clinical Trial Support
Q3-2026 Clinical Trial Support Trial count as of the end of the respective periods © 2026 CRYOPORT, INC. 14
Slide 15: Q3-2026 and 9M-2026 Revenue
Q3-2026 and 9M-2026 Revenue © 2026 CRYOPORT, INC. 15
Slide 16: Condensed Consolidated Statements of Operations
Cryopor., Ine. and Subsidiaries Condensed Consolidated Statements of Operations ‘Three Months Ended ‘Nine Months Ended ‘September 30, September 20, (unaudited) (unaudited) [in thousands, excent share and pershare data) 2026 2025 2026 E 24758 $83,031 § 19,575, 63,558 Life Sclences Services revenue $
Slide 17: Q3-2026 and 9M-2026 Balance Sheets
Q3-2026 and 9M-2026 Balance Sheets © 2026 CRYOPORT, INC. 17
Slide 18: Q3-2026 and 9M-2026 Adjusted EBITDA
Q3-2026 and 9M-2026 Adjusted EBITDA © 2026 CRYOPORT, INC. 18